Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 13 Parkinson's papers of 10,688 | 0.65 |
| pathways Reactome | 17 pathways; mostly iron and oxidative stress | 0.80 |
No case: the score is under the bar. Receipt 10251
Sealed predictions
- SMAD2 in dopamine neurons, braak+0.02 (p 0.962) → +0.50 (p 0.168)receipt 10260
Swarm cases
receipt 10260: SMAD2 in dopamine neurons, braak
- power
- full sample +0.23 (p 0.365, n 18), 95% CI -0.27 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.351, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.20 (p 0.429, n 18). could be the mix.
- skeptic
- leave-one-out range +0.15 to +0.40, sign flips 0; without severely affected donors +0.23 (p 0.365, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SMAD2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts